Paul Tudor Jones sees potential market rally after late October
HORSHAM, Pa. - STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company focused on dermatologic treatments with a current market capitalization of $8.7 million, announced today the completion of its registered direct offering, raising approximately $2.42 million in gross proceeds. According to InvestingPro data, the company has been quickly burning through cash and operates with a significant debt burden.
The company sold 1,097,547 shares of common stock at $2.204 per share, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. The offering, which closed on September 4, was conducted under a shelf registration statement previously declared effective by the Securities and Exchange Commission.
STRATA plans to use the net proceeds for working capital and general corporate purposes, according to the company’s press release statement.
The offering was made through a prospectus supplement filed with the SEC on September 3, 2025, as part of the company’s effective registration statement on Form S-3.
STRATA Skin Sciences develops and markets in-office treatment systems for various skin conditions, including psoriasis, vitiligo, and acne. The company’s product portfolio includes the XTRAC excimer laser, VTRAC lamp systems, and TheraClearX Acne Therapy System.
The company operates through a partnership model that provides healthcare providers with treatment devices on a fee-per-treatment basis rather than requiring equipment purchases, along with training, maintenance, and marketing support.
In other recent news, Strata Skin Sciences reported a 9% decline in total revenue for the second quarter of 2025, with earnings amounting to $7.7 million compared to the same period last year. Despite this decrease, the company expressed optimism for the latter half of the year, citing potential reimbursement rate increases and expanded market opportunities. Additionally, Strata Skin Sciences announced a registered direct offering, raising approximately $2.42 million by selling 1,097,547 shares at $2.204 each. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. In another development, the company’s Elevate 360 consulting program has reportedly led to business growth for partner clinics utilizing its XTRAC excimer laser technology. These clinics have benefited from the program’s marketing solutions, business system optimization, and patient retention tactics. These recent developments highlight Strata Skin Sciences’ ongoing efforts to strengthen its financial position and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.